Holen Sie sich die Stockscreener-App
1.41
3.42%
-0.05
Schlusskurs vom Vortag:
$1.46
Offen:
$1.54
24-Stunden-Volumen:
878.17K
Relative Volume:
0.67
Marktkapitalisierung:
$398.65M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.04M
KGV:
-1.7195
EPS:
-0.82
Netto-Cashflow:
$-122.99M
1W Leistung:
-10.19%
1M Leistung:
-25.79%
6M Leistung:
-50.35%
1J Leistung:
-26.56%
1-Tages-Spanne:
$1.41
$1.54
1-Wochen-Bereich:
$1.41
$1.60
52-Wochen-Spanne:
$1.41
$3.45
Erasca Inc Stock (ERAS) Company Profile
Firmenname
Erasca Inc
Sektor
Branche
Telefon
(858) 465-6511
Adresse
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Vergleichen Sie ERAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
1.41 | 398.65M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Eingeleitet | Jefferies | Buy |
| 2024-03-11 | Eingeleitet | CapitalOne | Overweight |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-30 | Eingeleitet | Mizuho | Buy |
| 2023-02-24 | Eingeleitet | Goldman | Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Erasca stock hits 52-week low at $1.5 amid market challenges By Investing.com - Investing.com South Africa
Erasca stock hits 52-week low at $1.5 amid market challenges - Investing.com
Metastatic Pancreatic Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Investor’s Toolkit: Key Ratios for Assessing Erasca Inc (ERAS)’s Performance - The Dwinnex
Erasca Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Erasca Inc [ERAS] Records 200-Day SMA of $2.5522 - Knox Daily
Pyxis Oncology Inc [PYXS] stock for 174,364 USD was acquired by Connealy Pamela Ann - Knox Daily
BlackBerry Ltd [BB] Records 200-Day SMA of $2.77 - Knox Daily
Erasca (NASDAQ:ERAS) Stock Price Down 6.1%What's Next? - MarketBeat
Metric Deep Dive: Understanding Erasca Inc (ERAS) Through its Ratios - The Dwinnex
Erasca Inc (ERAS) is a good investment, but the stock may be undervalued - US Post News
Erasca (NASDAQ:ERAS) Trading Up 6.6%Time to Buy? - MarketBeat
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - The Manila Times
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire Inc.
Erasca: Future 'Streamlined' But Still Uncertain (NASDAQ:ERAS) - Seeking Alpha
What Are You Thinking About Investing In Erasca Inc (NASDAQ: ERAS) Stock? - Stocks Register
Erasca’s Naporafenib Is Shaping Up Nicely For NRASm Melanoma (NASDAQ:ERAS) - Seeking Alpha
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround - MSN
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN
Erasca (NASDAQ:ERAS) Stock Price Down 6.2%Here's What Happened - MarketBeat
JPMorgan Chase & Co. Sells 13,100 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Acquired by Barclays PLC - Defense World
Erasca Highlights Strategic Focus at Healthcare Conference - TipRanks
Jane Street Group LLC Trims Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca (NASDAQ:ERAS) Trading Down 8.7%What's Next? - MarketBeat
Erasca (NASDAQ:ERAS) Upgraded at Bank of America - Defense World
Erasca (NASDAQ:ERAS) Shares Up 3%Still a Buy? - MarketBeat
Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Principal Financial Group Inc. - Defense World
Erasca (NASDAQ:ERAS) Rating Increased to Buy at Bank of America - MarketBeat
Erasca (NASDAQ:ERAS) Shares Gap UpWhat's Next? - MarketBeat
Erasca to Present at J.P. Morgan Healthcare Conference 2025: RAS/MAPK Cancer Innovations - StockTitan
Franklin Resources Inc. Invests $181,000 in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca (NASDAQ:ERAS) Trading Up 7.6%Should You Buy? - MarketBeat
Geode Capital Management LLC Raises Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Geode Capital Management LLC Has $12.30 Million Position in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Barclays PLC Increases Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment - ShareCast
State Street Corp Acquires 3,569,440 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Purchased by State Street Corp - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires New Stake in Erasca, Inc. (NASDAQ:ERAS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $994,000 in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Finanzdaten der Erasca Inc-Aktie (ERAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):